BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31888346)

  • 1. Impact of Donor and Recipient
    Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
    Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
    [No Abstract]   [Full Text] [Related]  

  • 2. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
    Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
    J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
    J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
    Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
    Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
    Moes DJ; van der Bent SA; Swen JJ; van der Straaten T; Inderson A; Olofsen E; Verspaget HW; Guchelaar HJ; den Hartigh J; van Hoek B
    Eur J Clin Pharmacol; 2016 Feb; 72(2):163-74. PubMed ID: 26521259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of donor-recipient combinational CYP3A5 genotypes on tacrolimus dosing in Chinese DDLT adult recipients.
    Liu J; Chen D; Yao B; Guan G; Liu C; Jin X; Wang X; Liu P; Sun Y; Zang Y
    Int Immunopharmacol; 2020 Mar; 80():106188. PubMed ID: 31931373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
    Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
    J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.
    Li L; Zhu M; Li DY; Guo HL; Hu YH; Xu ZY; Jing X; Chen F; Zhao F; Li YM; Xu J; Jiao Z
    Int Immunopharmacol; 2021 Sep; 98():107827. PubMed ID: 34284341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
    Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
    Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.
    Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL
    J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
    Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
    Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
    Chen YK; Han LZ; Xue F; Shen CH; Lu J; Yang TH; Zhang JJ; Xia Q
    PLoS One; 2014; 9(10):e109464. PubMed ID: 25310192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.
    Pinon M; De Nicolò A; Pizzol A; Antonucci M; D'Avolio A; Serpe L; Dell'Olio D; Catalano S; Tandoi F; Romagnoli R; Canaparo R; Calvo PL
    Sci Rep; 2021 Jan; 11(1):443. PubMed ID: 33432012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
    Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
    J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach.
    Guy-Viterbo V; Baudet H; Elens L; Haufroid V; Lacaille F; Girard M; Debray D; Chardot C; Reding R; Wallemacq P; Musuamba F
    Pharmacogenomics; 2014 Jun; 15(9):1207-21. PubMed ID: 25141896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.